Adial Pharmaceuticals
Manufacturing · Virginia, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
4870 Sadler Rd Ste 300, Glen Allen, Virg...Phone Number
(804) 487-8196Website
www.adial.comRevenue
-Stock Symbol
ADILIndustry
About Adial Pharmaceuticals
Adial Pharmaceuticals Org Chart
Is Adial Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check out if Adial Pharmaceuticals is spiking on competitors!
Click to see if Adial Pharmaceuticals had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Adial Pharmaceuticals
Adial Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Adial Pharmaceuticals launches new products
Check if Adial Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Adial Pharmaceuticals recently announced quarterly report
Funding: Get notified immidiatlly once Adial Pharmaceuticals has new funding data
Recommended Actions
Reach out to Masked Content who joined Adial Pharmaceuticals as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Adial Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Adial Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Adial Pharmaceuticals.
Adial Pharmaceuticals Tech Stack
A closer look at the technologies used by Adial Pharmaceuticals
Most Recent Scoops
Adial Pharmaceuticals News & Media
Adial Pharmaceuticals Acquires Azora and Raises $26.8M PIPE, With More on Milestones
Adial Pharmaceuticals completed a stock-for-stock acquisition of Azora Therapeutics, issuing common and preferred shares that will leave former Azora holders with roughly 86.9% of the combined company on a fully diluted basis prior to the financing and note exchange. Concurrently, Adial secured $26…Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing
- Acquisition of Azora and concurrent private placement positions the combined company to advance its pipeline through key clinical milestones in ulcerative colitis, including Phase 1 initiation in mid-2027Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
GLEN ALLEN, Va., May 11, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2026 first quarter ended March 31, 2026.Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045
New U.S. utility patent application targeting patient populations with demonstrated heightened responsiveness to ondansetron treatment, reinforcing Adial’s precision-medicine approach New U.S. utility patent application targeting patient populations with demonstrated heightened responsiveness to ondansetron treatment, reinforcing Adial’s precision-medicine approach
Top Manufacturing Companies
Frequently Asked Questions Regarding Adial Pharmaceuticals
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions.... Read More
